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SHORT COMMUNICATION
The relationship between weightloss and interleukin 6 in non-small-cell lung
cancer
HR Scott', DC McMillan2, A Crilly3, CS McArdle2 and R Milroy'
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Smary Markers of the inflammatory response, interleukin 6, C-reactive protein, albumin and full blood
count, were measured in non-small-cell lung cancer (NSCLC) patients (n=21) with and without weight loss
(>5%). There were significant increases in circulating C-reactive protein (P<0.001), interleukin 6 (P<0.01)
and platelets (P<0.01) in the weight-losing group. Moreover, there was a statistically significnt correlation
(r=0.785, P<0.001) between interleukin 6 and C-reactive protein concentrations. These results are consistent
with interleukin 6 and the acute phase response promoting weight loss in NSCLC.
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Lung cancer, of which non-small-cell lung cancer (NSCLC)
constitutes about 80%, is the greatest cause of cancer-related
death worldwide. It presents late with advanced incurable
disease for which treatment options are limited (Splinter,
1991). Weight loss is a common symptom in patients with
non-small-cell lung cancer and significantly associated with
poor prognosis in such patients (Sridhar et al., 1990; Ihde
and Minna, 1991; Thorogood et al., 1992; Espinosa et al.,
1995).
It has been proposed that mediators of the acute phase
response (produced by the host in response to the tumour)
are important in promoting weight loss in cancer patients
(Fearon, 1992). For example, animal work suggests a major
role for interleukin 6 in cancer cachexia (Strassman et al.,
1992). Indeed, in humans interleukin 6 appears to be a
primary regulator of the acute phase response (Heinrich et
al., 1990). Furthermore, reports have documented an increase
in circulating interleukin 6 concentrations in gastrointestinal
cancer (Fearon et al., 1991; Falconer et al., 1994b) and lung
cancer patients (Yanagawa et al., 1995).
We present preliminary data describing the relationship
between weight loss, interleukin 6 and the acute phase
response in patients with NSCLC.
Materials and methods
Patients (n=21) who, within the previous 12 months, had
either none or more than 5% weight loss were studied. All
patients had cytologically or histologically confirmed NSCLC
and had no clinical or radiological evidence of infection. No
patient had received non-steroidal anti-inflammatory therapy
or systemic corticosteroid therapy or had undergone any anti-
cancer treatment.
The time from diagnosis to study for all patients was
within one month. Tumour staging was performed according
to the American Thoracic Society TNM criteria (Mountain,
1991) using results of clinical findings, chest radiograph, and
where appropriate bronchoscopy, liver ultrasound, isotope
bone scan and computerised tomography (CT) scan of
thorax. The study was approved by the local ethics
committee. All patients were informed of the purpose and
procedure of the study and all gave written consent.
The patients were weighed and questioned carefully about
their pre-illness weight and weight loss. The degree of weight
loss before the study was confirmed in all patients by
reference to the patients hospital and GP records.
Blood samples were removed for routine laboratory
measurements of albumin, C-reactive protein, total white
blood cell count, differential white cell and platelet counts.
Aliquots of serum were frozen for interleukin 6 analysis.
Interleukin 6 was measured by [3H]thymidine incorpora-
tion in the B9 cell line (Aarden et al., 1987), dependent on
interleukin 6 for growth, using 100 p1 serum samples and
standard (88/154 National Institute Biological Standards and
Controls, Porton Down, UK) diluted 2-fold serially (8
dilutions). The detection limit of the assay was 0.15 ml-'.
Data are presented as median and range. Where
appropriate data were tested for statistical significance using
Mann-Whitney U-test (Minitab, CA, USA).
Results
The clinical characteristics of the lung cancer patients studied
are shown in Table I. The group with no weight loss were
well matched in terms of sex, age and tumour stage compared
with the group with >5% weight loss. However, the group
with more than 5% weight loss had on average significantly
lower weight (P<0.01) and body mass index (P<0.001)
which was outwith the normal range (20-25)
The measured blood parameters of the two groups are
shown in Table II. Circulating albumin concentrations were
significantly reduced in the group ofpatients with weight loss
compared with the group without weight loss. In contrast,
there were significant increases in circulating C-reactive
protein (P<0.001), interleukin 6 (P<0.01) and platelets
Table I Characteristics of NSCLC patients
No weight loss >5% weight loss
(n =9} (n =12) P-value
Sex(M/F) 8,1 10/2 NS
Age 60(51 -83) 67(57-78) NS
Weight (kg) 70(54-80) 48(37-80) 0.003
BMI (kg m-2) 24.6(21.2 -27.9) 16.7(12.8 -23.5) 0.0007
Tumour stage
I and I 5 7 NS
III 3 3 NS
IV 1 2 NS
Median (range); BMI, body mass index; NS, not significant.
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Table H Blood parameters of NSCLC with or without weight loss
No weight loss >5% weight loss
(n =9) (n =12)
Median (range) Median (range) P-value
Albumin 43 37 0.02
(g r') (35-48) (24-47)
CRP 15 145 0.0002
(mg r1) (<5-43) (37-160)
IL-6 2.0 18 0.001
(U mE') (<0.2-14) (4-62)
WBC 7.6 10.2 0.04
(106 mrl) (5.1-15.2) (8.2-36.8)
Neutrophil count 5.1 8.4 0.055
(106 mE') (3.3-14.0) (5.3-30.0)
Lymphocyte count 1.9 1.6 0.50
(106 mE') (0.7-2.3) (0.7-6.2)
Platelet count 267 422 0.003
(106 mrl) (210-364) (285-565)
CRP, C-reactive protein; IL-6, interleukin 6; WBC, white blood cell
count.
(P<0.01) in the weight-losing group. There were also
increases in white blood cell and neutrophil counts which
approached statistical significance at the 5% level.
In the weight-losing group we examined the relationship
between the rate of weight loss and the circulating
concentrations of interleukin 6 and C-reactive protein. In
this small group (n= 12) there were no significant correlations
between the rate of weight loss and C-reactive protein or
interleukin 6. There was a statistically significant Spearman
rank correlation (r=0.785, P<0.001) between interleukin 6
and C-reactive protein concentrations in both patient groups.
The present study demonstrates for the first time, in NSCLC
patients, the relationship between weight loss and the acute
phase response. The circulating concentrations of interleukin
6 were consistently higher in the group with at least 5%
weight loss compared with the group without weight loss.
Recent animal work (Strassman et al., 1992; Ohe et al., 1993)
indicates that interleukin 6 has a pivotal role in the
development of cancer cachexia. The circulating concentra-
tions of interleukin 6 were consistently higher in the group
with at least 5% weight loss compared with the group
without weight loss. This suggests that interleukin 6 may
have a role in the development of cachexcia in these patients.
In the patients studied there was a statistically significant
correlation between circulating concentrations of interleukin
6 and C-reactive protein (P<0.0O1). These results are
consistent with the role of interleukin 6 as a primary
mediator of the acute phase protein response. The presence
of a more active acute phase response in the weight-losing
group was confirmed by the increased circulating white blood
cell and neutrophil counts.
It has been reported that administration of recombinant
human interleukin 6 increases the number of circulating
platelets in primates (Mayer et al., 1991). This is consistent
with the findings of the present study in which an increase in
platelet count in the weight-losing group (P<0.01) was
associated with an increase in interleukin 6 concentrations. In
contrast, Yanagawa and coworkers (1995) have reported no
increase in blood platelet counts associated with increased
interleukin 6 concentrations in lung cancer patients.
However, unlike the present study several tumour types
(including small-cell carcinoma) were studied and this may
have been a confounding factor.
The mechanisms by which the on-going acute phase
response may promote weight loss in cancer have not been
fully elucidated. However, there is evidence that the
associated alterations in fat, protein and energy metabolism
(Selberg et al., 1990; Fearon et al., 1991; McMillan et al.,
1994; Falconer et al., 1994a) are detrimental to the patient
and may contribute to reduced survival (Falconer et al.,
1995).
It has been reported recently that ibuprofen (a non-
steroidal anti-inflammatory agent) can moderate protein
synthesis, energy expenditure and circulating interleukin 6
concentrations in cancer patients with an acute phase
response (Preston et al., 1995; Wigmore et al., 1995;
McMillan et al., 1995). These studies together with the
present study suggest a potential role for non-steroidal anti-
inflammatory agents such as ibuprofen in the treatment of
weight loss in NSCLC.
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